In the TME, CD56brightCD16- NK cells, the primary NK subtype in TME, can release VEGF, placenta growth factor, and IL-8/CXCL8, promoting angiogenesis and potentially supporting tumor growth (181). This evidence concerns the gene CXCL8 and neoplasm.